Literature DB >> 8123648

High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults.

J O Johansson1, K Landin, L Tengborn, T Rosén, B A Bengtsson.   

Abstract

Hypopituitary patients on routine replacement therapy except growth hormone (GH) have an increased risk of death from cardiovascular diseases compared with healthy subjects. Untreated GH deficiency might explain the premature death from vascular disease. Plasminogen activator inhibitor (PAI-1) activity, fibrinogen, insulin, blood lipid, and blood pressure levels were studied in 20 GH-deficient adults (10 men, 10 women) 50 +/- 11 years old with routine hormone replacement therapy (except GH) and compared with 20 healthy control subjects matched for sex, age, and body mass index. GH-deficient subjects had a higher waist-to-hip circumference ratio (P < .001), serum triglycerides (P < .02), PAI-1 activity (13.2 +/- 10.6 versus 6.8 +/- 4.8 U/mL [P < .05]), and fibrinogen (3.2 +/- 0.7 versus 2.4 +/- 0.6 g/L [P < .001]) and lower blood glucose (P < .05) compared with control subjects. Blood pressure, insulin, and cholesterol levels were similar. The aberrations found in this study might contribute to an increased atherothrombotic propensity and play a role in the pathogenesis of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123648     DOI: 10.1161/01.atv.14.3.434

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  24 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

4.  Growth hormone and the heart in growth hormone deficiency-what have we learned so far?

Authors:  Jörgen Isgaard; Antonio Cittadini
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

Review 5.  Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation.

Authors:  F Tanriverdi; Z Karaca; K Unluhizarci; F Kelestimur
Journal:  Endocrine       Date:  2014-05-11       Impact factor: 3.633

6.  Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome.

Authors:  Antonio Mancini; Chantal Di Segni; Carmine Bruno; Giulio Olivieri; Francesco Guidi; Andrea Silvestrini; Elisabetta Meucci; Patrick Orlando; Sonia Silvestri; Luca Tiano; Alfredo Pontecorvi
Journal:  Endocrine       Date:  2017-11-15       Impact factor: 3.633

7.  Effect of Doppler flow and lipid studies in a geriatric population--increased flow left internal carotid artery only.

Authors:  J G Devlin; P Garry; D Fitzgerald
Journal:  Ir J Med Sci       Date:  1999 Jul-Sep       Impact factor: 1.568

8.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

9.  Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity.

Authors:  Hideo Makimura; Takara Stanley; David Mun; Cindy Chen; Jeffrey Wei; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

10.  [Reduced incidence of side-effects of growth hormone substitution in 404 patients with hypophyseal insufficiency. Results of a multicenter indications study].

Authors:  C Wüster; U Melchinger; T Eversmann; J Hensen; P Kann; A von zur Mühlen; M B Ranke; H Schmeil; H Steinkamp; U Tuschy
Journal:  Med Klin (Munich)       Date:  1998-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.